March 2018 Investor Presentation
Filed with ASX · · 34 pages · English
Melbourne, Australia (19 March 2018): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) provides a copy of the attached March 2018 Investor Presentation, ahead of final Phase 1b breast cancer results with PTX-200. For women with locally advanced ER+, HER2 negative breast cancer, typical expectations are a response rate of 25%. Prescient is currently undertaking t
Prescient Therapeutics Limited on 6ix
In the deck
Earlier from Prescient Therapeutics
- December 2017 Appendix 4C - Quarterly
- Clinical Trial Updates
- Clinical Hold Lifted on PTX-200 Breast Cancer Trial
- PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
- September 2017 Appendix 4C - Quarterly
Later from Prescient Therapeutics
- PTX-200 Phase 1b Breast Cancer Trial Results
- Response to Aware Query
- March 2018 Appendix 4C - Quarterly
- US Patent Granted for PTX-200 for Ovarian Cancer Treatment
- June 2018 Appendix 4C - Quarterly
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics